60 Degrees Pharma Q2 FY26 net loss widens 30.6% to $2.26 million; revenue more than doubles to $207,898

• 60 Degrees Pharmaceuticals posted a net loss attributable to shareholders of $2.26 million for Q2 2026, widening from $1.73 million a year earlier.
• Product Revenues - net of Discounts and Rebates more than doubled to $207,898, up 105.98% year over year.
• Operating loss widened to $2.27 million, while gross margin fell 23.09 percentage points to 27.32%.
• Cash and cash equivalents totaled $1.02 million at June 30, 2026; net cash used in operating activities rose to $4.97 million for H1 2026.
• Quarter included a Runway Health partnership to expand Arakoda access, an FDA objection on Australian Chestnut Extract marketing, and an FSU patent license.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-001860), on August 14, 2026, and is solely responsible for the information contained therein.